From: Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation
 | Overall patients (n = 503) | P value | ||
---|---|---|---|---|
No NeOAF (n = 263) | NeOAF to SR (n = 165) | NeOAF to AF (n = 75) | ||
Infection site, n (%) | ||||
 Respiratory tract | 168 (63.9) | 112 (67.9) | 48 (64.0) |  |
 Urinary tract | 57 (21.7) | 35 (21.2) | 14 (18.7) |  |
 Gastrointestinal | 23 (8.7) | 9 (5.5) | 5 (6.7) |  |
 Others | 15 (5.7) | 9 (5.5) | 8 (10.7) |  |
SOFA score | 7.0 ± 3.2 | 7.6 ± 3.0 | 9.3 ± 3.2bc | <0.01 |
APACHE II score | 21.6 ± 5.5 | 22.8 ± 5.8 | 24.6 ± 6.1b | <0.01 |
Total organ failurea, n | 2 (1–3) | 2 (1–3) | 3 (2–4) |  |
 Neurologic failure | 87 (33.1) | 49 (29.7) | 39 (52.0)bc | <0.01 |
 Circulatory failure | 118 (44.9) | 82 (49.7) | 57 (76.0)bc | <0.01 |
 Respiratory failure | 229 (87.1) | 150 (90.9) | 71 (94.7) | 0.13 |
 Hepatic failure | 8 (3.0) | 4 (2.4) | 8 (10.7)bc | <0.01 |
 Renal failure | 86 (32.7) | 65 (39.4) | 39 (52.0)b | <0.01 |
 Hematologic failure | 9 (3.4) | 5 (3.0) | 4 (5.3) | 0.66 |
Vasopressor use, n (%) | ||||
 Dopamine use | 95 (36.3) | 64 (38.8) | 49 (65.3)bc | <0.01 |
 Norepinephrine use | 80 (30.4) | 58 (35.2) | 48 (64.0)bc | <0.01 |
Intervention, n (%) | ||||
 Ventilator use | 221 (84.0) | 143 (86.7) | 69 (92.0) | 0.21 |
 New-onset dialysis | 50 (19.0) | 35 (21.2) | 19 (25.3) | 0.48 |